| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
George Golumbeski is Director at STTK, with reported holdings spanning 3 companies. George Golumbeski's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $307K at current prices.
Our model assigns George Golumbeski a below-average insider score of 40/100, based on 3 past trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -21.7%.
George Golumbeski's largest disclosed position is in STTK as Director, worth about $299K. Net of sales, the STTK filings show accumulation of 54,613 shares.
George Golumbeski has 21 Form 4 filings on record from February 2015 to June 2026, across 5 companies: Director at Acumen Pharmaceuticals (ABOS), 2025–2026; Director at Shattuck Labs (STTK), 2020–2026; Director at MURA, 2025, and 2 more.
The 29 reported transactions were 16 option or other derivative awards, 4 option exercises, 3 open-market purchases and 3 open-market sales, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $200K and 2 sales worth about $2.2M.
The largest open-market purchase was 28,330 shares of STTK at an average $3.63 on April 26, 2022, about $103K. Twelve months later STTK was down 21%.
The largest open-market sale was 13,500 shares of ENTA at an average $90.06 on February 12, 2019, about $1.2M.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 26, 2022 | STTK Shattuck Labs, Inc. | Director | Buy | 28,330 | $3.63 | $102,837.90 | +107.8% | +16.2% | -20.5% | |
| Apr 22, 2022 | STTK Shattuck Labs, Inc. | Director | Buy | 26,283 | $3.69 | $96,979.59 | New | +20.8% | -24.9% | |
| Mar 4, 2019 | ENTA Enanta Pharmaceuticals Inc | Director | Sale+OE | 9,280 | $103.65 | $961,897.06 | - | - | - | |
| Feb 12, 2019 | ENTA Enanta Pharmaceuticals Inc | Director | Sale+OE | 13,500 | $90.06 | $1,215,853.49 | - | - | - |